Increasing value and reducing waste in biomedical research regulation and management

The Lancet

Volumn 383, Issue 9912, 2014, Pages 176-185

  Al Shahi Salman, Rustam ^a   Beller, Elaine ^b   Kagan, Jonathan ^c   Hemminki, Elina ^d   Phillips, Robert S ^e   Savulescu, Julian ^f   Macleod, Malcolm ^a   Wisely, Janet ^g   Chalmers, Iain ^h  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b BOND UNIVERSITY   (Australia)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^e UNIVERSITY OF YORK   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g Health Research Authority   (United Kingdom)

^h James Lind Initiative   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PRACTICE; CLINICAL RESEARCH; ELECTRONIC MEDICAL RECORD; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH PRACTITIONER; HUMAN; INFORMED CONSENT; MANAGEMENT; MANAGER; MEDICAL INFORMATION SYSTEM; MEDICAL RESEARCH; MULTICENTER STUDY (TOPIC); NATIONAL HEALTH SERVICE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROFESSIONAL STANDARD; PROTOCOL COMPLIANCE; QUALITATIVE RESEARCH; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESEARCH ETHICS; REVIEW; SCIENTIST; STUDY DESIGN; SYSTEMATIC REVIEW (TOPIC); WASTE MANAGEMENT;

EID: 84892148591     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)62297-7     Document Type: Review

References (101)

1. Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence. Lancet 2009; 374: 86-89
2. Academy of Medical Sciences. A new pathway for the regulation and governance of health research, 2011. http://www.acmedsci.ac. uk/p47prid88.html (accessed Dec 2, 2013).
3. Katz J. The Nuremberg Code and the Nuremberg Trial. A reappraisal. JAMA 1996; 276: 1662-66
4. Pappworth MH. Human guinea pigs: a warning. Twentieth Century 1962; 171: 66-75
5. Beecher HK. Ethics and clinical research. N Engl J Med 1966; 274: 1354-60
6. Guide for the Care and Use of Laboratory Animals. Institute for Laboratory Animal Research, Commission of Life Sciences, National Research Council. Washington, DC: National Academy Press, 1996
7. Shaw S, Boynton PM, Greenhalgh T. Research governance: where did it come from, what does it mean? J R Soc Med 2005; 98: 496-502
8. Shaw S, Barrett G. Research governance: regulating risk and reducing harm? J R Soc Med 2006; 99: 14-19
9. Savulescu J, Chalmers I, Blunt J. Are research ethics committees behaving unethically? Some suggestions for improving performance and accountability. BMJ 1996; 313: 1390-93
10. Califf RM. Clinical trials bureaucracy: unintended consequences of well-intentioned policy. Clin Trials 2006; 3: 496-502
11. Animals (Scientifi c Procedures) Act. London: Her Majesty's Stationery Offi ce, 1986
12. The European Parliament and the Council of the European Union. Directive 2010/63/EU on the protection of animals used for scientifi c purposes. Offi cial Journal of the European Union 2010; 276: 33-79
13. Russell WMS, Burch RL. The principles of humane experimental technique. St Albans: Universities Federation for Animal Welfare, 1959
14. Smithells RW. Iatrogenic hazards and their eff ects. Postgrad Med J 1975; 52 (suppl): 39-52
15. The Lancet. Medical ethics: should medicine turn the other cheek? Lancet 1990; 336: 846-47
16. Chalmers I, Lindley RI. Double standards on informed consent to treatment. In: Doyal L, Tobias JS, eds. Informed consent in medical research. London: BMJ Publications, 2001: 266-75
17. Warlow C. A new NHS research strategy. Lancet 2006; 367: 12-13
18. Slowther A, Boynton P, Shaw S. Research governance: ethical issues. J R Soc Med 2006; 99: 65-72
19. Jester PM, Tilden SJ, Li Y, Whitley RJ, Sullender WM. Regulatory challenges: lessons from recent West Nile virus trials in the United States. Contemp Clin Trials 2006; 27: 254-59
20. Bollyky TJ, Cockburn IM, Berndt E. Bridging the gap: improving clinical development and the regulatory pathways for health products for neglected diseases. Clin Trials 2010; 7: 719-34
21. Reith C, Landray M, Devereaux PJ, et al. Randomized clinical trials- removing unnecessary obstacles. N Engl J Med 2013; 369: 1061-65
22. Duley L, Antman K, Arena J, et al. Specifi c barriers to the conduct of randomized trials. Clin Trials 2008; 5: 40-48
23. Christie DR, Gabriel GS, Dear K. Adverse eff ects of a multicentre system for ethics approval on the progress of a prospective multicentre trial of cancer treatment: how many patients die waiting? Intern Med J 2007; 37: 680-86
24. Neaton JD, Babiker A, Bohnhorst M, et al. Regulatory impediments jeopardizing the conduct of clinical trials in Europe funded by the National Institutes of Health. Clin Trials 2010; 7: 705-18
25. da Silva ME, Coeli CM, Ventura M, et al. Informed consent for record linkage: a systematic review. J Med Ethics 2012; 38: 639-42
26. Hansson MG. Need for a wider view of autonomy in epidemiological research. BMJ 2010; 340: c2335
27. Stjernschantz Forsberg J, Hansson MG, Eriksson S. Biobank research: who benefi ts from individual consent? BMJ 2011; 343: d5647
28. Barrett G, Cassell JA, Peacock JL, Coleman MP, for the National Cancer Registry. National survey of British public's views on use of identifi able medical data by the National Cancer Registry. BMJ 2006; 332: 1068-72
29. Tupasela A, Sihvo S, Snell K, Jallinoja P, Aro AR, Hemminki E. Attitudes towards biomedical use of tissue sample collections, consent, and biobanks among Finns. Scand J Public Health 2010; 38: 46-52
30. Kho ME, Duff ett M, Willison DJ, Cook DJ, Brouwers MC. Written informed consent and selection bias in observational studies using medical records: systematic review. BMJ 2009; 338: b866
31. Dilts DM, Sandler AB. Invisible barriers to clinical trials: the impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials. J Clin Oncol 2006; 24: 4545-52
32. Kramer JM, Smith PB, Califf RM. Impediments to clinical research in the United States. Clin Pharmacol Ther 2012; 91: 535-41
33. McMahon AD, Conway DI, Macdonald TM, McInnes GT. The unintended consequences of clinical trials regulations. PLoS Med 2009; 3: e1000131
34. Frewer LJ, Coles D, van der Lans IA, Schroeder D, Champion K, Apperley JF. Impact of the European clinical trials directive on prospective academic clinical trials associated with BMT. Bone Marrow Transplant 2011; 46: 443-47
35. Hedgecoe A, Carvalho F, Lobmayer P, Raka F. Research ethics committees in Europe: implementing the directive, respecting diversity. J Med Ethics 2006; 32: 483-86
36. Lambers Heerspink HJ, Dobre D, Hillege HL, Grobbee DE, de Zeeuw D. Does the European clinical trials directive really improve clinical trial approval time? Br J Clin Pharmacol 2008; 66: 546-50
37. European Forum for Good Clinical Practice (EFGCP). Impact on clinical research of European legislation (ICREL). June 15, 2009. European Commission, Directorate Research. http://www.efgcp.be/ICREL/(accessed Dec 2, 2013)
38. Campbell MK, Snowdon C, Francis D, et al. Recruitment to randomised trials: strategies for trial enrollment and participation study. The STEPS study. Health Technol Assess 2007; 11: ix-105
39. Sully BG, Julious SA, Nicholl J. A reinvestigation of recruitment to randomised, controlled, multicenter trials: a review of trials funded by two UK funding agencies. Trials 2013; 14: 166
40. Ford JG, Howerton MW, Lai GY, et al. Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. Cancer 2008; 112: 228-42
41. McDonald AM, Knight RC, Campbell MK, et al. What infl uences recruitment to randomised controlled trials? A review of trials funded by two UK funding agencies. Trials 2006; 7: 9
42. Fern L, Davies S, Eden T, et al, for the National Cancer Research Institute (NCRI) Teenage and Young Adult Clinical Studies Development Group. Rates of inclusion of teenagers and young adults in England into National Cancer Research Network clinical trials: report from the National Cancer Research Institute (NCRI) Teenage and Young Adult Clinical Studies Development Group. Br J Cancer 2008; 99: 1967-74
43. Fonville AF, Samarasekera N, Hutchison A, Perry D, Roos YB, Al-Shahi Salman R. Eligibility for randomized trials of treatments specifi cally for intracerebral hemorrhage: community-based study. Stroke 2013; 44: 2729-34
44. Getz KA, Wenger J, Campo RA, Seguine ES, Kaitin KI. Assessing the impact of protocol design changes on clinical trial performance. Am J Ther 2008; 15: 450-57
45. Prescott RJ, Counsell CE, Gillespie WJ, et al. Factors that limit the quality, number and progress of randomised controlled trials. Health Technol Assess 1999; 3: 1-143
46. Roberts I, Prieto-Merino D, Shakur H, Chalmers I, Nicholl J. Eff ect of consent rituals on mortality in emergency care research. Lancet 2011; 377: 1071-72
47. Bakobaki J, Joff e N, Burdett S, Tierney J, Meredith S, Stenning S. A systematic search for reports of site monitoring technique comparisons in clinical trials. Clin Trials 2012; 9: 777-80
48. Macefi eld RC, Beswick AD, Blazeby JM, Lane JA. A systematic review of on-site monitoring methods for health-care randomised controlled trials. Clin Trials 2013; 10: 104-24
49. Chalmers I. Health Research Authority's great leap forward on UK trial registration. BMJ 2013; 347: f5776
50. Chalmers I. A guide to patient-led good controlled trials. Lancet 2000; 356: 774
51. Evans I, Thornton H, Chalmers I, Glasziou P. Testing treatments: better research for better healthcare, 2nd edn. London: Pinter and Martin, 2011
52. Blunt J, Savulescu J, Watson AJ. Meeting the challenges facing research ethics committees: some practical suggestions. BMJ 1998; 316: 58-61
53. McJoynt TA, Hirzallah MA, Satele DV, Pitzen JH, Alberts SR, Rajkumar SV. Building a protocol expressway: the case of Mayo Clinic Cancer Center. J Clin Oncol 2009; 27: 3855-60
54. Al-Shahi R. Research ethics committees in the UK-The pressure is now on research and development departments. J R Soc Med 2005; 98: 444-47
55. Fudge N, Redfern J, Wolfe C, McKevitt C. Streamlined research governance: are we there yet? BMJ 2010; 341: c4625
56. Millum J, Wendler D, Emanuel EJ. The 50th anniversary of the declaration of Helsinki: progress but many remaining challenges. JAMA 2013; published online Oct 23. DOI:10.1001/jama.2013.281632
57. Gotzsche PC. Defi ciencies in proposed new EU regulation of clinical trials. BMJ 2012; 345: e8522
58. Medicines and Healthcare Products Regulatory Agency. Riskadapted approaches to the management of clinical trials of investigational medicinal products. Sept 7, 2012. http://www.mhra. gov.uk/Howweregulate/Medicines/ Inspectionandstandards/GoodClinicalPractice/News/CON126145 (accessed Dec 2, 2013).
59. Smyth RL. A risk adapted approach to the governance of clinical trials. BMJ 2011; 343: d6756
60. Peddicord D, Waldo AB, Boutin M, Grande T, Gutierrez L Jr. A proposal to protect privacy of health information while accelerating comparative eff ectiveness research. Health Aff (Millwood) 2010; 29: 2082-90
61. Savulescu J, Hope T. Ethics of research. In: Skorupski J, ed. The Routledge Companion to Ethics. Abingdon: Routledge, 2010: 781-95
62. Junghans C, Feder G, Hemingway H, Timmis A, Jones M. Recruiting patients to medical research: double blind randomised trial of "opt-in" versus "opt-out" strategies. BMJ 2005; 331: 940
63. Rogers CG, Tyson JE, Kennedy KA, Broyles RS, Hickman JF. Conventional consent with opting in versus simplifi ed consent with opting out: an exploratory trial for studies that do not increase patient risk. J Pediatr 1998; 132: 606-11
64. Treweek S, Mitchell E, Pitkethly M, et al. Strategies to improve recruitment to randomised controlled trials. Cochrane Database Syst Rev 2010; 1: MR000013
65. Ennis L, Wykes T. Impact of patient involvement in mental health research: longitudinal study. Br J Psychiatry 2013; 203: 381-86
66. Watson JM, Torgerson DJ. Increasing recruitment to randomised trials: a review of randomised controlled trials. BMC Med Res Methodol 2006; 6: 34
67. Sustainable Trials Study Group. Towards sustainable clinical trials. BMJ 2007; 334: 671-73
68. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003; 290: 1624-32
69. Staa TP, Goldacre B, Gulliford M, et al. Pragmatic randomised trials using routine electronic health records: putting them to the test. BMJ 2012; 344: e55
70. Edwards SJ, Lilford RJ, Thornton J, Hewison J. Informed consent for clinical trials: in search of the "best" method. Soc Sci Med 1998; 47: 1825-40
71. Godlee F, Chalmers I. Publishing information about ongoing clinical trials for patients. BMJ 2010; 340: c725
72. Edwards PJ, Roberts I, Clarke MJ, et al. Methods to increase response to postal and electronic questionnaires. Cochrane Database Syst Rev 2009; 3: MR000008
73. Rendell JM, Merritt RD, Geddes JR. Incentives and disincentives to participation by clinicians in randomised controlled trials. Cochrane Database Syst Rev 2007; 2: MR000021
74. Fletcher B, Gheorghe A, Moore D, Wilson S, Damery S. Improving the recruitment activity of clinicians in randomised controlled trials: a systematic review. BMJ Open 2012; 2: e000496
75. Bakobaki JM, Rauchenberger M, Joff e N, McCormack S, Stenning S, Meredith S. The potential for central monitoring techniques to replace on-site monitoring: fi ndings from an international multi-centre clinical trial. Clin Trials 2012; 9: 257-64
76. Venet D, Doff agne E, Burzykowski T, et al. A statistical approach to central monitoring of data quality in clinical trials. Clin Trials 2012; 9: 705-13
77. Journot V, Pignon JP, Gaultier C, et al, for the Optimon Collaborative Group. Validation of a risk-assessment scale and a risk-adapted monitoring plan for academic clinical research studies-The Pre-Optimon study. Contemp Clin Trials 2011; 32: 16-24
78. Tudur Smith C, Stocken DD, Dunn J, et al. The value of source data verifi cation in a cancer clinical trial. PLoS One 2012; 7: e51623
79. Baigent C, Harrell FE, Buyse M, Emberson JR, Altman DG. Ensuring trial validity by data quality assurance and diversifi cation of monitoring methods. Clin Trials 2008; 5: 49-55
80. Chalmers I, Altman DG, McHaffi e H, Owens N, Cooke RW. Data sharing among data monitoring committees and responsibilities to patients and science. Trials 2013; 14: 102
81. Weisfeld V, English RA, Claiborne AB. Public engagement and clinical trials. New models and disruptive technologies. Workshop summary. Washington, DC: The National Academies Press; 2011
82. Chalmers I. It's offi cial: evaluative research must become part of routine care in the NHS. J R Soc Med 2000; 93: 555-56
83. Department of Health (Research and Development Directorate). Best Research for Best Health: a new national health research strategy. Jan 25, 2006. London: Department of Health, 2006
84. GMC. Good Medical Practice. London: General Medical Council, 2006
85. GMC. Good Medical Practice. London: General Medical Council, 2013
86. Roberts I, Chaudhry B, Chalmers I. New GMC guidance takes a major, ethically fl awed, backward step. BMJ 2013; 346: f3879
87. Stiller CA, Eatock EM. Patterns of care and survival for children with acute lymphoblastic leukaemia diagnosed between 1980 and 1994. Arch Dis Child 1999; 81: 202-08
88. Unguru Y. The successful integration of research and care: how pediatric oncology became the subspecialty in which research defi nes the standard of care. Pediatr Blood Cancer 2011; 56: 1019-25
89. O'Leary M, Krailo M, Anderson JR, Reaman GH, for the Children's Oncology Group. Progress in childhood cancer: 50 years of research collaboration, a report from the Children's Oncology Group. Semin Oncol 2008; 35: 484-93
90. Vist GE, Bryant D, Somerville L, Birminghem T, Oxman AD. Outcomes of patients who participate in randomized controlled trials compared to similar patients receiving similar interventions who do not participate. Cochrane Database Syst Rev 2008; 3: MR000009
91. Stiller CA, Kroll ME, Pritchard-Jones K. Population survival from childhood cancer in Britain during 1978-2005 by eras of entry to clinical trials. Ann Oncol 2012; 23: 2464-69
92. Majumdar SR, Roe MT, Peterson ED, Chen AY, Gibler WB, Armstrong PW. Better outcomes for patients treated at hospitals that participate in clinical trials. Arch Intern Med 2008; 168: 657-62
93. Clarke M, Loudon K. Eff ects on patients of their healthcare practitioner's or institution's participation in clinical trials: a systematic review. Trials 2011; 12: 16
94. Papanikolaou PN, Christidi GD, Ioannidis JP. Patient outcomes with teaching versus nonteaching healthcare: a systematic review. PLoS Med 2006; 3: e341
95. Chalmers I. Addressing uncertainties about the eff ects of treatments off ered to NHS patients: whose responsibility? J R Soc Med 2007; 100: 440-41
96. Rothwell PM. Funding for practice-oriented clinical research. Lancet 2006; 368: 262-66
97. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev 2012; 12: MR000033
98. Warlow C. Over-regulation of clinical research: a threat to public health. Clin Med 2005; 5: 33-38
99. Whitney SN, Schneider CE. Viewpoint: a method to estimate the cost in lives of ethics board review of biomedical research. J Intern Med 2011; 269: 396-402
100. Califf RM, Morse MA, Wittes J, et al. Toward protecting the safety of participants in clinical trials. Control Clin Trials 2003; 24: 256-71
101. Chalmers I. Regulation of therapeutic research is compromising the interests of patients. Int J Pharm Med 2007; 21: 395-404.